Identification of inositol polyphosphate 4-phosphatase type II as a novel tumor resistance biomarker in human laryngeal cancer HEp-2 cells

Cancer Biology and Therapy

Volumn 13, Issue 13, 2012, Pages 1307-1318

  Kim, Jae Sung ^a   Yun, Hong Shik ^a,b   Um, Hong Duck ^a   Park, Jong Kuk ^a   Lee, Kee Ho ^a   Kang, Chang Mo ^a   Lee, Su Jae ^b   Hwang, Sang Gu ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Akt pathway; Chemoresistance; ERK signaling; HEp 2 cells; INPP4B; Laryngeal cancer; Radioresistance

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE TYPE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL PROTECTION; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE LIBRARY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTRACELLULAR SIGNALING; LARYNX CANCER; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HCT116 CELLS; HUMANS; LARYNGEAL NEOPLASMS; MCF-7 CELLS; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868356696     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21788     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6; PMID:11668491; http://dx.doi.org/10.1002/ijc.1440.
2. Lefebvre JL. Laryngeal preservation in head and neck cancer: multidisciplinary approach. Lancet Oncol 2006; 7:747-55; PMID:16945770; http://dx.doi.org/10.1016/S1470-2045(06)70860-9.
3. Nix PA, Greenman J, Cawkwell L, Stafford N. Radioresistant laryngeal cancer: beyond the TNM stage. Clin Otolaryngol Allied Sci 2004; 29:105-14; PMID:15113291; http://dx.doi.org/10.1046/j.1365-2273.2003.00796.x.
4. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5:516-25; PMID:15965493; http://dx.doi.org/10.1038/nrc1650.
5. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9:288-96; PMID:18308254; http://dx.doi.org/10.1016/S1470- 2045(08)70073-1.
6. Haffty BG, Glazer PM. Molecular markers in clinical radiation oncology. Oncogene 2003; 22:5915-25; PMID:12947398; http://dx.doi.org/10.1038/sj.onc. 1206704.
7. Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008; 134:363-9; PMID:18427001; http://dx.doi.org/10.1001/archotol.134.4.363.
8. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiationresistant MCF-7 breast cancer cells. Cancer Res 2005; 65:10338-46; PMID:16288023; http://dx.doi.org/10.1158/0008-5472.CAN-04- 4614.
9. Guo G, Yan-Sanders Y, Lyn-Cook BD, Wang T, Tamae D, Ogi J, et al. Manganese superoxide dismutase- mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 2003; 23:2362-78; PMID:12640121; http://dx.doi.org/10.1128/MCB.23.7.2362-2378.2003.
10. Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RD. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 1990; 82:607-12; PMID:1968980; http://dx.doi.org/10. 1093/jnci/82.7.607.
11. Henness S, Davey MW, Harvie RM, Davey RA. Fractionated irradiation of H69 small-cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2, and topoisomerase IIalpha expression. Int J Radiat Oncol Biol Phys 2002; 54:895-902; PMID:12377343; http://dx.doi.org/10.1016/S0360- 3016(02)03037-7.
12. Ryu JS, Um JH, Kang CD, Bae JH, Kim DU, Lee YJ, et al. Fractionated irradiation leads to restoration of drug sensitivity in MDR cells that correlates with down-regulation of P-gp and DNA-dependent protein kinase activity. Radiat Res 2004; 162:527-35;PMID:15624307; http://dx.doi.org/10.1667/ RR3260.
13. Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, et al. Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res 2008; 170:41-8; PMID:18582150; http://dx.doi.org/10.1667/RR0986.1.
14. Seve M, Chimienti F, Devergnas S, Favier A. In silico identification and expression of SLC30 family genes: an expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression. BMC Genomics 2004; 5:32; PMID:15154973; http://dx.doi.org/10.1186/1471-2164-5-32.
15. Oh J, Lee J, Woo JM, Choi E, Park I, Han C, et al. Systematic identification and integrative analysis of novel genes expressed specifically or predominantly in mouse epididymis. BMC Genomics 2006; 7:314; PMID:17166261; http://dx.doi.org/10.1186/1471-2164-7-314.
16. Kim JS, Ryoo ZY, Chun JS. Cytokine-like 1 (Cytl1) regulates the chondrogenesis of mesenchymal cells. J Biol Chem 2007; 282:29359-67; PMID:17644814; http://dx.doi.org/10.1074/jbc.M700965200.
17. Kim JS, Chang JW, Yun HS, Yang KM, Hong EH, Kim DH, et al. Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEp-2 cells via reactive oxygen species production. Proteomics 2010; 10:2589-604; PMID:20461716; http://dx.doi.org/10. 1002/pmic.200900523.
18. Norris FA, Auethavekiat V, Majerus PW. The isolation and characterization of cDNA encoding human and rat brain inositol polyphosphate 4-phosphatase. J Biol Chem 1995; 270:16128-33; PMID:7608176; http://dx.doi.org/10.1074/jbc.270. 27.16128.
19. Norris FA, Atkins RC, Majerus PW. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem 1997; 272:23859-64; PMID:9295334; http://dx.doi.org/10.1074/jbc.272.38.23859.
20. Gewinner C, Wang ZC, Richardson A, Teruya- Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009; 16:115-25; PMID:19647222; http://dx.doi.org/10.1016/j.ccr.2009.06.006.
21. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006; 443:651-7; PMID:17035995; http://dx.doi.org/10. 1038/nature05185.
22. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009; 34:115-27; PMID:19299143; http://dx.doi.org/10.1016/j.tibs.2009.01.003.
23. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 2008; 9:162-76; PMID:18216772; http://dx.doi.org/10.1038/nrm2335.
24. Barnache S, Le Scolan E, Kosmider O, Denis N, Moreau-Gachelin F. Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene 2006; 25:1420-3; PMID:16247441; http://dx.doi.org/10.1038/sj.onc. 1209187.
25. Duan S, Bleibel WK, Huang RS, Shukla SJ, Wu X, Badner JA, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007; 67:5425-33; PMID:17545624; http://dx.doi.org/10.1158/0008-5472.CAN-06-4431.
26. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, et al. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics 2009; 93:52-61; PMID:18804159; http://dx.doi.org/10.1016/j. ygeno.2008.08.002.
27. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96; PMID:12947395; http://dx.doi.org/10.1038/sj.onc.1206701.
28. Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006; 66:9601-8; PMID:17018617; http://dx.doi.org/10.1158/0008-5472.CAN-06-2627.
29. Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in nonsmall cell lung cancer. Cancer Res 2007; 67:1163-9; PMID:17283151; http://dx.doi.org/10.1158/0008-5472.CAN-06-2037.
30. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009; 108:180-94; PMID:19293033; http://dx.doi.org/10.1016/S0929-6646(09)60051-6.
31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501; PMID:12094235; http://dx.doi.org/10.1038/nrc839.
32. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 2004; 24:8778-89; PMID:15367694; http://dx.doi.org/10.1128/MCB.24.19.8778-8789. 2004.
33. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441:523-7; PMID:16680151; http://dx.doi.org/10.1038/ nature04809.
34. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58; PMID:11902585; http://dx.doi.org/10.1038/nrc706.
35. Evans A, Bates V, Troy H, Hewitt S, Holbeck S, Chung YL, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008; 61:377-93; PMID:17520257; http://dx.doi.org/10. 1007/s00280-007-0480-1.
36. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003; 179:801-11; PMID:14652668; http://dx.doi.org/10.1007/s00066-003-1150-9.
37. Pan JS, Cai JY, Xie CX, Zhou F, Zhang ZP, Dong J, et al. Interacting with HBsAg compromises resistance of jumping translocation breakpoint protein to ultraviolet radiation-induced apoptosis in 293FT cells. Cancer Lett 2009; 285:151-6; PMID:19487072; http://dx.doi.org/10.1016/j.canlet.2009.05.009.
38. Jung EU, Yoon JH, Lee YJ, Lee JH, Kim BH, Yu SJ, et al. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett 2010; 298:9-15; PMID:20573444; http://dx.doi.org/10.1016/j.canlet.2010.05.020.
39. Sasaki J, Kofuji S, Itoh R, Momiyama T, Takayama K, Murakami H, et al. The PtdIns(3,4)P(2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death. Nature 2010; 465:497-501; PMID:20463662; http://dx.doi.org/10.1038/ nature09023.
40. Nystuen A, Legare ME, Shultz LD, Frankel WN. A null mutation in inositol polyphosphate 4-phosphatase type I causes selective neuronal loss in weeble mutant mice. Neuron 2001; 32:203-12; PMID:11683991; http://dx.doi.org/10.1016/ S0896-6273(01)00468-8.
41. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133:403-14; PMID:18455982; http://dx.doi.org/10.1016/j.cell.2008.04. 013.
42. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget 2011; 2:321-8; PMID:21487159.
43. Kisseleva MV, Cao L, Majerus PW. Phosphoinositidespecific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death. J Biol Chem 2002; 277:6266-72; PMID:11706019; http://dx.doi.org/10.1074/jbc.M105969200.
44. Kim JS, Park ZY, Yoo YJ, Yu SS, Chun JS. p38 kinase mediates nitric oxide-induced apoptosis of chondrocytes through the inhibition of protein kinase C zeta by blocking autophosphorylation. Cell Death Differ 2005; 12:201-12; PMID:15665819; http://dx.doi.org/10.1038/sj.cdd.4401511.